Literature DB >> 23165462

Systematic review and meta-analysis of vancomycin-induced nephrotoxicity associated with dosing schedules that maintain troughs between 15 and 20 milligrams per liter.

S J van Hal1, D L Paterson, T P Lodise.   

Abstract

In an effort to maximize outcomes, recent expert guidelines recommend more-intensive vancomycin dosing schedules to maintain vancomycin troughs between 15 and 20 mg/liter. The widespread use of these more-intensive regimens has been associated with an increase in vancomycin-induced nephrotoxicity reports. The purpose of this systematic literature review is to determine the nephrotoxicity potential of maintaining higher troughs in clinical practice. All studies pertaining to vancomycin-induced nephrotoxicity between 1996 and April 2012 were identified from PubMed, Embase, Cochrane Controlled Trial Registry, and Medline databases and analyzed according to Cochrane guidelines. Of the initial 240 studies identified, 38 were reviewed, and 15 studies met the inclusion criteria. Overall, higher troughs (≥ 15 mg/liter) were associated with increased odds of nephrotoxicity (odds ratio [OR], 2.67; 95% confidence interval [CI], 1.95 to 3.65) relative to lower troughs of <15 mg/liter. The relationship between a trough of ≥ 15 mg/liter and nephrotoxicity persisted when the analysis was restricted to studies that examined only initial trough concentrations (OR, 3.12; 95% CI, 1.81 to 5.37). The relationship between troughs of ≥ 15 mg/liter and nephrotoxicity persisted after adjustment for covariates known to independently increase the risk of a nephrotoxicity event. An incremental increase in nephrotoxicity was also observed with longer durations of vancomycin administration. Vancomycin-induced nephrotoxicity was reversible in the majority of cases, with short-term dialysis required only in 3% of nephrotoxic episodes. The collective literature indicates that an exposure-nephrotoxicity relationship for vancomycin exists. The probability of a nephrotoxic event increased as a function of the trough concentration and duration of therapy.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23165462      PMCID: PMC3553731          DOI: 10.1128/AAC.01568-12

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  63 in total

1.  Optimal dose of vancomycin for treating methicillin-resistant Staphylococcus aureus pneumonia in critically ill patients.

Authors:  J Chung; J M Oh; E M Cho; H J Jang; S B Hong; C M Lim; Y S Koh
Journal:  Anaesth Intensive Care       Date:  2011-11       Impact factor: 1.669

2.  Risk factors for renal failure in pediatric patients with acute myeloid leukemia: a retrospective cohort study.

Authors:  Brian T Fisher; Theoklis E Zaoutis; Kateri H Leckerman; Russell Localio; Richard Aplenc
Journal:  Pediatr Blood Cancer       Date:  2010-10       Impact factor: 3.167

3.  In vivo evidences suggesting the role of oxidative stress in pathogenesis of vancomycin-induced nephrotoxicity: protection by erdosteine.

Authors:  Faruk Oktem; Meltem Koyuncu Arslan; Fehmi Ozguner; Ozden Candir; H Ramazan Yilmaz; Metin Ciris; Efkan Uz
Journal:  Toxicology       Date:  2005-08-19       Impact factor: 4.221

4.  Linezolid in methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a randomized, controlled study.

Authors:  Richard G Wunderink; Michael S Niederman; Marin H Kollef; Andrew F Shorr; Mark J Kunkel; Alice Baruch; William T McGee; Arlene Reisman; Jean Chastre
Journal:  Clin Infect Dis       Date:  2012-01-12       Impact factor: 9.079

5.  Effects of targeting higher vancomycin trough levels on clinical outcomes and costs in a matched patient cohort.

Authors:  Ravina Kullar; Susan L Davis; Thomas N Taylor; Keith S Kaye; Michael J Rybak
Journal:  Pharmacotherapy       Date:  2012-03       Impact factor: 4.705

6.  Predictors and outcome of acute kidney injury in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome.

Authors:  Amit Lahoti; Hagop Kantarjian; Abdulla K Salahudeen; Farhad Ravandi; Jorge E Cortes; Stefan Faderl; Susan O'Brien; William Wierda; Gloria N Mattiuzzi
Journal:  Cancer       Date:  2010-09-01       Impact factor: 6.860

7.  Elevated vancomycin trough is not associated with nephrotoxicity among inpatient veterans.

Authors:  Kavitha K Prabaker; Thuong P-H Tran; Tamara Pratummas; Matthew Bidwell Goetz; Christopher J Graber
Journal:  J Hosp Med       Date:  2011-11-15       Impact factor: 2.960

8.  Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections.

Authors:  Pamela A Moise-Broder; Alan Forrest; Mary C Birmingham; Jerome J Schentag
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

9.  Association of vancomycin serum concentrations with outcomes in patients with gram-positive bacteremia.

Authors:  A E Zimmermann; B G Katona; K I Plaisance
Journal:  Pharmacotherapy       Date:  1995 Jan-Feb       Impact factor: 4.705

10.  Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury.

Authors:  Ravindra L Mehta; John A Kellum; Sudhir V Shah; Bruce A Molitoris; Claudio Ronco; David G Warnock; Adeera Levin
Journal:  Crit Care       Date:  2007       Impact factor: 9.097

View more
  139 in total

Review 1.  Determining the optimal vancomycin daily dose for pediatrics: a meta-analysis.

Authors:  Geisa Cristina da Silva Alves; Samuel Dutra da Silva; Virginia Paula Frade; Danielle Rodrigues; André de Oliveira Baldoni; Whocely Victor de Castro; Cristina Sanches
Journal:  Eur J Clin Pharmacol       Date:  2017-08-04       Impact factor: 2.953

2.  Balancing vancomycin efficacy and nephrotoxicity: should we be aiming for trough or AUC/MIC?

Authors:  Karisma Patel; Ashley S Crumby; Holly D Maples
Journal:  Paediatr Drugs       Date:  2015-04       Impact factor: 3.022

3.  Vancomycin-Associated Cast Nephropathy.

Authors:  Yosu Luque; Kevin Louis; Chantal Jouanneau; Sandrine Placier; Emmanuel Esteve; Dominique Bazin; Eric Rondeau; Emmanuel Letavernier; Alice Wolfromm; Clément Gosset; Anna Boueilh; Maren Burbach; Perrine Frère; Marie-Christine Verpont; Sophie Vandermeersch; Dominique Langui; Michel Daudon; Vincent Frochot; Laurent Mesnard
Journal:  J Am Soc Nephrol       Date:  2017-01-12       Impact factor: 10.121

4.  Effect of Vancomycin-Associated Acute Kidney Injury on Incidence of 30-Day Readmissions among Hospitalized Veterans Affairs Patients with Skin and Skin Structure Infections.

Authors:  Nimish Patel; Nicholas Stornelli; Ryan J Sangiovanni; David B Huang; Thomas P Lodise
Journal:  Antimicrob Agents Chemother       Date:  2020-09-21       Impact factor: 5.191

5.  Vancomycin Prophylaxis for Total Joint Arthroplasty: Incorrectly Dosed and Has a Higher Rate of Periprosthetic Infection Than Cefazolin.

Authors:  Michael M Kheir; Timothy L Tan; Ibrahim Azboy; Dean D Tan; Javad Parvizi
Journal:  Clin Orthop Relat Res       Date:  2017-07       Impact factor: 4.176

6.  Identification of Vancomycin Exposure-Toxicity Thresholds in Hospitalized Patients Receiving Intravenous Vancomycin.

Authors:  Evan J Zasowski; Kyle P Murray; Trang D Trinh; Natalie A Finch; Jason M Pogue; Ryan P Mynatt; Michael J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2017-12-21       Impact factor: 5.191

7.  Evaluation of a New Vancomycin Dosing Protocol in Morbidly Obese Patients.

Authors:  Desiree E Kosmisky; Carrie L Griffiths; Megan A Templin; James Norton; Kelly E Martin
Journal:  Hosp Pharm       Date:  2015-10-14

8.  Large discrepancies in linezolid use between French teaching hospitals: A comment on "Antimicrobial stewardship and linezolid".

Authors:  G G Aubin; D Boutoille; S Corvec; J Caillon; A Caillaud; F Moal; D Navas
Journal:  Int J Clin Pharm       Date:  2015-03-12

9.  Impact of Pharmacy Practice Model Expansion on Pharmacokinetic Services: Optimization of Vancomycin Dosing and Improved Patient Safety.

Authors:  Zhe Han; Natasha N Pettit; Emily M Landon; Benjamin D Brielmaier
Journal:  Hosp Pharm       Date:  2017-04

10.  Large retrospective evaluation of the effectiveness and safety of ceftaroline fosamil therapy.

Authors:  Anthony M Casapao; Susan L Davis; Viktorija O Barr; Kenneth P Klinker; Debra A Goff; Katie E Barber; Keith S Kaye; Ryan P Mynatt; Leah M Molloy; Jason M Pogue; Michael J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2014-02-18       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.